Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
2024年3月18日 - 8:30PM
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a
rare disease therapeutics company, today announced that it will
host a conference call and live audio webcast on Thursday, March
28, 2024, at 4:30 p.m. ET, to review its corporate and financial
results for the fourth quarter and full year 2023.
The link to the audio webcast will be accessible
via the Investor Relations section of the Company’s website,
https://investors.zevra.com/.
To join the meeting by conference call, use the dial-in
information below.
- (800) 245-3047
(U.S.)
- +1 (203) 518-9765
(International)
- Conference ID:
ZVRAQ423
An archive of the webcast will be available for
90 days beginning at approximately 5:30 p.m. ET, on March 28, 2024,
at https://investors.zevra.com/.
About Zevra Therapeutics
Zevra Therapeutics is a rare disease company
combining science, data, and patient needs to create
transformational therapies for diseases with limited or no
treatment options. Our mission is to bring life-changing
therapeutics to people living with rare diseases. With unique,
data-driven development and commercialization strategies, the
Company is overcoming complex drug development challenges to make
new therapies available to the rare disease community.
For more information, please visit www.zevra.com
or follow us on X (formerly Twitter)
and LinkedIn. Caution Concerning
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, including without limitation statements regarding upcoming
events or Zevra’s participation at such events. Forward-looking
statements are based on information currently available to Zevra
and its current plans or expectations. They are subject to several
known and unknown uncertainties, risks, and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. These and other important factors are described in
detail in the "Risk Factors" section of Zevra’s Annual Report on
Form 10-K for the year ended December 31, 2022, as updated in
Zevra’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, and Zevra’s other filings with the Securities
and Exchange Commission. While we may elect to update such
forward-looking statements at some point in the future, except as
required by law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Although we believe
the expectations reflected in such forward-looking statements are
reasonable, we cannot assure that such expectations will prove
correct. These forward-looking statements should not be relied upon
as representing our views as of any date after the date of this
press release.
Zevra Contact
Nichol Ochsner+1 (732) 754-2545nochsner@zevra.com
Russo Partners Contacts
Adanna G. Alexander, Ph.D.+1 (646)
942-5603adanna.alexander@russopartnersllc.com
Ignacio Guerrero-Ros, Ph.D.+1 (646)
942-5604ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (NASDAQ:ZVRA)
過去 株価チャート
から 4 2024 まで 5 2024
Zevra Therapeutics (NASDAQ:ZVRA)
過去 株価チャート
から 5 2023 まで 5 2024